Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
NETWORK
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map
CUSTOM DERMATOLOGY SEARCH:
Loading

Drug Treatments For Skin Disease Introduced in 1999

Drug Class Generic/Trade/ Company Names Indication Approving Regulatory Agency

HIV and AIDS

Abacavir Sulfate
Ziagen
Glaxo Wellcome

  • A nucleoside analogue reverse transcriptase inhibitor for the treatment of HIV and AIDS

HPB – Ottawa

Male Pattern Hair Loss

Minoxidil 2% Topical Solution
Taisho

  • Recommended for OTC use

Japanese Pharmaceutical and Medical Safety Bureau

Finasteride
Propecia
1mg Tablets Merck Sharp & Dohme

  • An additional indication of male-pattern hair loss

UK MCA

Oncologic Agents

Aldesleukin
Proleukin
Chiron

  • An additional indication for treatment of malignant metastatic melanoma

HPB – Ottawa

Alitretinoin
Panretin
Gel 0.1% Ligand Pharmaceutical

  • For topical treatment of cutaneous lesions in patients with AIDS related Kaposi’s Sarcoma

US FDA
HPB – Ottawa

Allovectin-7
Vical

  • For treatment of invasive and metastatic melanoma

US FDA
(orphan drug status)

Bexarotene
Targretin
75mg Capsules Ligand Pharmaceuticals

  • For treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to one or more prior systemic treatments for CTCL

US FDA

Denileukin Diftitox
Ontak
Ligand Pharmaceuticals

  • For the treatment of CTCL

US FDA
(accelerated approval)

G-3139
Vical

  • For the treatment of advanced malignant melanoma

US FDA
(fast-track designation)

Interferon Alpha-2a
Roferon-A
Hoffmann-La Roche

  • For the adjuvant treatment of malignant melanoma patients who are at risk for relapse following resection

European Commission
(CPMP)

Melanoma Lysate
Melacine Therapeutic Vaccine
Schering-Plough

  • For the treatment of late stage (IV) melanoma

HPB – Ottawa

Methoxsalen
Uvadex
Therakos

  • For palliative treatment of the skin manifestations of CTCL that are unresponsive to other forms of therapy

US FDA

Osteoporosis

Alendronate
Fosamax
Merck

  • For treatment of glucocorticoid induced osteoporosis in patients receiving glucocorticoids in a daily dosage equivalent to ≥ 7.5mg prednisone and who have low bone mineral density

US FDA

Pediculocides

Malathion
Ovide 0.5% Lotion
Medicis Pharmaceutical

  • For treatment of head lice and their ova

For treatment of head lice and their ova US FDA

Pyrethrins/Piperonyl Butoxide
Rid Aerosol Foam Mousse
Pfizer

  • For treatment of head lice

US FDA

Photodynamic Therapy

Aminolevulinic Acid
Levulan
Photodynamic Therapy DUSA Pharmaceuticals

  • For treatment of actinic keratoses of the face and scalp

US FDA

Topical Anesthetics

Lidocaine 5%
Lidoderm
Patch Endo Pharmaceuticals

  • For treatment of postherpetic neuralgia

US FDA

Lidocaine/Prilocaine
EMLA
Cream Astra

  • An additional indication for use in pediatric patients

US FDA

Vaginal Atrophy

Estradiol
Estradiol Transdermal System
Wyeth Ayerst Laboratories

  • For the treatment of vulvar and vaginal atrophy

US FDA


In this issue:

  1. Synopsis of Laser Assisted Hair Removal Systems
  2. Drug Treatments For Skin Disease Introduced in 1999
  3. Update on Drugs and Drug News - Number 3 1999